The immunogenicity of the ChAdOx1 nCoV-19 vaccination in participants with underlying comorbidity diseases: A prospective cohort study
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) increases mortality rates in older adults and those with comorbidities. Individuals with certain comorbidities may have a poor immune response and require early booster vaccines. We aimed to assess the immune response after two doses of Ch...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-08-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2023.2251850 |
| _version_ | 1797673069594017792 |
|---|---|
| author | Thachanun Porntharukchareon Wipada Chartisathian Manassamon Navinpipat Chayanee Samdaengpan Kunsuda Cheirsilpa Aimwipa Lueprasitsakul Supanat Worawichawong Viroj Muangsillapasart Pratya Pumuthaivirat Bothamai Dechates Supamas Sirisreetreerux Taweegrit Siripongboonsitti Vimonsri Rangsrisaeneepitak Kerati Jirawattanapalin Kriangkrai Tawinprai |
| author_facet | Thachanun Porntharukchareon Wipada Chartisathian Manassamon Navinpipat Chayanee Samdaengpan Kunsuda Cheirsilpa Aimwipa Lueprasitsakul Supanat Worawichawong Viroj Muangsillapasart Pratya Pumuthaivirat Bothamai Dechates Supamas Sirisreetreerux Taweegrit Siripongboonsitti Vimonsri Rangsrisaeneepitak Kerati Jirawattanapalin Kriangkrai Tawinprai |
| author_sort | Thachanun Porntharukchareon |
| collection | DOAJ |
| description | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) increases mortality rates in older adults and those with comorbidities. Individuals with certain comorbidities may have a poor immune response and require early booster vaccines. We aimed to assess the immune response after two doses of ChAdOx1 nCoV-19 vaccine, at 84-day intervals, in participants with the following comorbidities; diabetes mellitus; obesity; cardiovascular disease; chronic kidney disease; rheumatological disease; cirrhosis; hematological disease; hematological malignancy; or solid malignancy. The study was conducted at Chulabhorn Hospital in Thailand, with healthy healthcare workers serving as the control group. Of the 769 participants, 352 were in the healthy cohort and 417 were in the comorbidity cohort, all received at least one dose of vaccine. Anti-RBD total antibody levels were evaluated on Day 0, Day 84, and Day 112. The results at Day 112 (4 weeks after the second dose) showed that individuals with comorbidities had a poor immune response compared to healthy individuals, especially those with hematological malignancy and solid malignancy. The geometric mean concentration (GMC) of anti-RBD antibody in the comorbidity cohort was significantly lower than that in the healthy cohort: 433.66 BAU/ml (95% CI 334.62–562.01) versus 1096.14 BAU/ml (95% CI 1010.26–1189.33), respectively. The geometric mean ratio (GMR) between the two cohorts was 0.40 (95% CI 0.30–0.52, p < .001). This study concluded that individuals with comorbidities, particularly hematological and solid malignancies, had poor immune responses and may require an early booster vaccine to prevent infection and death. |
| first_indexed | 2024-03-11T21:39:12Z |
| format | Article |
| id | doaj.art-d9fefc7a82fe41f29f104928efe1ccb9 |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T21:39:12Z |
| publishDate | 2023-08-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-d9fefc7a82fe41f29f104928efe1ccb92023-09-26T13:25:52ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2023-08-0119210.1080/21645515.2023.22518502251850The immunogenicity of the ChAdOx1 nCoV-19 vaccination in participants with underlying comorbidity diseases: A prospective cohort studyThachanun Porntharukchareon0Wipada Chartisathian1Manassamon Navinpipat2Chayanee Samdaengpan3Kunsuda Cheirsilpa4Aimwipa Lueprasitsakul5Supanat Worawichawong6Viroj Muangsillapasart7Pratya Pumuthaivirat8Bothamai Dechates9Supamas Sirisreetreerux10Taweegrit Siripongboonsitti11Vimonsri Rangsrisaeneepitak12Kerati Jirawattanapalin13Kriangkrai Tawinprai14Chulabhorn Royal AcademyChulabhorn Royal AcademyChulabhorn Royal AcademyChulabhorn Royal AcademyChulabhorn Royal AcademyChulabhorn Royal AcademyChulabhorn Royal AcademyChulabhorn Royal AcademyChulabhorn Royal AcademyChulabhorn Royal AcademyChulabhorn Royal AcademyChulabhorn Royal AcademyBurapha UniversityChulabhorn Royal AcademyChulabhorn Royal AcademySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) increases mortality rates in older adults and those with comorbidities. Individuals with certain comorbidities may have a poor immune response and require early booster vaccines. We aimed to assess the immune response after two doses of ChAdOx1 nCoV-19 vaccine, at 84-day intervals, in participants with the following comorbidities; diabetes mellitus; obesity; cardiovascular disease; chronic kidney disease; rheumatological disease; cirrhosis; hematological disease; hematological malignancy; or solid malignancy. The study was conducted at Chulabhorn Hospital in Thailand, with healthy healthcare workers serving as the control group. Of the 769 participants, 352 were in the healthy cohort and 417 were in the comorbidity cohort, all received at least one dose of vaccine. Anti-RBD total antibody levels were evaluated on Day 0, Day 84, and Day 112. The results at Day 112 (4 weeks after the second dose) showed that individuals with comorbidities had a poor immune response compared to healthy individuals, especially those with hematological malignancy and solid malignancy. The geometric mean concentration (GMC) of anti-RBD antibody in the comorbidity cohort was significantly lower than that in the healthy cohort: 433.66 BAU/ml (95% CI 334.62–562.01) versus 1096.14 BAU/ml (95% CI 1010.26–1189.33), respectively. The geometric mean ratio (GMR) between the two cohorts was 0.40 (95% CI 0.30–0.52, p < .001). This study concluded that individuals with comorbidities, particularly hematological and solid malignancies, had poor immune responses and may require an early booster vaccine to prevent infection and death.http://dx.doi.org/10.1080/21645515.2023.2251850chadox1 ncov-19vaccinecomorbidityimmunogenicitycovid-19 |
| spellingShingle | Thachanun Porntharukchareon Wipada Chartisathian Manassamon Navinpipat Chayanee Samdaengpan Kunsuda Cheirsilpa Aimwipa Lueprasitsakul Supanat Worawichawong Viroj Muangsillapasart Pratya Pumuthaivirat Bothamai Dechates Supamas Sirisreetreerux Taweegrit Siripongboonsitti Vimonsri Rangsrisaeneepitak Kerati Jirawattanapalin Kriangkrai Tawinprai The immunogenicity of the ChAdOx1 nCoV-19 vaccination in participants with underlying comorbidity diseases: A prospective cohort study Human Vaccines & Immunotherapeutics chadox1 ncov-19 vaccine comorbidity immunogenicity covid-19 |
| title | The immunogenicity of the ChAdOx1 nCoV-19 vaccination in participants with underlying comorbidity diseases: A prospective cohort study |
| title_full | The immunogenicity of the ChAdOx1 nCoV-19 vaccination in participants with underlying comorbidity diseases: A prospective cohort study |
| title_fullStr | The immunogenicity of the ChAdOx1 nCoV-19 vaccination in participants with underlying comorbidity diseases: A prospective cohort study |
| title_full_unstemmed | The immunogenicity of the ChAdOx1 nCoV-19 vaccination in participants with underlying comorbidity diseases: A prospective cohort study |
| title_short | The immunogenicity of the ChAdOx1 nCoV-19 vaccination in participants with underlying comorbidity diseases: A prospective cohort study |
| title_sort | immunogenicity of the chadox1 ncov 19 vaccination in participants with underlying comorbidity diseases a prospective cohort study |
| topic | chadox1 ncov-19 vaccine comorbidity immunogenicity covid-19 |
| url | http://dx.doi.org/10.1080/21645515.2023.2251850 |
| work_keys_str_mv | AT thachanunporntharukchareon theimmunogenicityofthechadox1ncov19vaccinationinparticipantswithunderlyingcomorbiditydiseasesaprospectivecohortstudy AT wipadachartisathian theimmunogenicityofthechadox1ncov19vaccinationinparticipantswithunderlyingcomorbiditydiseasesaprospectivecohortstudy AT manassamonnavinpipat theimmunogenicityofthechadox1ncov19vaccinationinparticipantswithunderlyingcomorbiditydiseasesaprospectivecohortstudy AT chayaneesamdaengpan theimmunogenicityofthechadox1ncov19vaccinationinparticipantswithunderlyingcomorbiditydiseasesaprospectivecohortstudy AT kunsudacheirsilpa theimmunogenicityofthechadox1ncov19vaccinationinparticipantswithunderlyingcomorbiditydiseasesaprospectivecohortstudy AT aimwipalueprasitsakul theimmunogenicityofthechadox1ncov19vaccinationinparticipantswithunderlyingcomorbiditydiseasesaprospectivecohortstudy AT supanatworawichawong theimmunogenicityofthechadox1ncov19vaccinationinparticipantswithunderlyingcomorbiditydiseasesaprospectivecohortstudy AT virojmuangsillapasart theimmunogenicityofthechadox1ncov19vaccinationinparticipantswithunderlyingcomorbiditydiseasesaprospectivecohortstudy AT pratyapumuthaivirat theimmunogenicityofthechadox1ncov19vaccinationinparticipantswithunderlyingcomorbiditydiseasesaprospectivecohortstudy AT bothamaidechates theimmunogenicityofthechadox1ncov19vaccinationinparticipantswithunderlyingcomorbiditydiseasesaprospectivecohortstudy AT supamassirisreetreerux theimmunogenicityofthechadox1ncov19vaccinationinparticipantswithunderlyingcomorbiditydiseasesaprospectivecohortstudy AT taweegritsiripongboonsitti theimmunogenicityofthechadox1ncov19vaccinationinparticipantswithunderlyingcomorbiditydiseasesaprospectivecohortstudy AT vimonsrirangsrisaeneepitak theimmunogenicityofthechadox1ncov19vaccinationinparticipantswithunderlyingcomorbiditydiseasesaprospectivecohortstudy AT keratijirawattanapalin theimmunogenicityofthechadox1ncov19vaccinationinparticipantswithunderlyingcomorbiditydiseasesaprospectivecohortstudy AT kriangkraitawinprai theimmunogenicityofthechadox1ncov19vaccinationinparticipantswithunderlyingcomorbiditydiseasesaprospectivecohortstudy AT thachanunporntharukchareon immunogenicityofthechadox1ncov19vaccinationinparticipantswithunderlyingcomorbiditydiseasesaprospectivecohortstudy AT wipadachartisathian immunogenicityofthechadox1ncov19vaccinationinparticipantswithunderlyingcomorbiditydiseasesaprospectivecohortstudy AT manassamonnavinpipat immunogenicityofthechadox1ncov19vaccinationinparticipantswithunderlyingcomorbiditydiseasesaprospectivecohortstudy AT chayaneesamdaengpan immunogenicityofthechadox1ncov19vaccinationinparticipantswithunderlyingcomorbiditydiseasesaprospectivecohortstudy AT kunsudacheirsilpa immunogenicityofthechadox1ncov19vaccinationinparticipantswithunderlyingcomorbiditydiseasesaprospectivecohortstudy AT aimwipalueprasitsakul immunogenicityofthechadox1ncov19vaccinationinparticipantswithunderlyingcomorbiditydiseasesaprospectivecohortstudy AT supanatworawichawong immunogenicityofthechadox1ncov19vaccinationinparticipantswithunderlyingcomorbiditydiseasesaprospectivecohortstudy AT virojmuangsillapasart immunogenicityofthechadox1ncov19vaccinationinparticipantswithunderlyingcomorbiditydiseasesaprospectivecohortstudy AT pratyapumuthaivirat immunogenicityofthechadox1ncov19vaccinationinparticipantswithunderlyingcomorbiditydiseasesaprospectivecohortstudy AT bothamaidechates immunogenicityofthechadox1ncov19vaccinationinparticipantswithunderlyingcomorbiditydiseasesaprospectivecohortstudy AT supamassirisreetreerux immunogenicityofthechadox1ncov19vaccinationinparticipantswithunderlyingcomorbiditydiseasesaprospectivecohortstudy AT taweegritsiripongboonsitti immunogenicityofthechadox1ncov19vaccinationinparticipantswithunderlyingcomorbiditydiseasesaprospectivecohortstudy AT vimonsrirangsrisaeneepitak immunogenicityofthechadox1ncov19vaccinationinparticipantswithunderlyingcomorbiditydiseasesaprospectivecohortstudy AT keratijirawattanapalin immunogenicityofthechadox1ncov19vaccinationinparticipantswithunderlyingcomorbiditydiseasesaprospectivecohortstudy AT kriangkraitawinprai immunogenicityofthechadox1ncov19vaccinationinparticipantswithunderlyingcomorbiditydiseasesaprospectivecohortstudy |